News

Participation in a clinical trial of vaccines for the prevention of meningococcal and pneumococcal infections in the pediatric population is being considered.

A new drug for the treatment of IBD will be tested at our center. The study will begin in July 2025, we invite patients for pre-selection!

A selection visit was successfully completed to participate in a simple, blind, randomized, parallel-group study comparing the efficacy, safety, immunogenicity, and pharmacodynamics of Stelara® iStileukin® drugs at the supportive stage of treatment for moderate to severe ulcerative colitis (UC) with ineffectiveness/loss of clinical response/intolerance to previous treatment, sponsored by GENERIUM JSC.", Russia